Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Renal Cell | 13 | 2023 | 3101 | 1.740 |
Why?
|
Kidney Neoplasms | 13 | 2023 | 4189 | 1.520 |
Why?
|
Receptors, Androgen | 1 | 2023 | 1049 | 0.600 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 11410 | 0.540 |
Why?
|
Lung Neoplasms | 4 | 2021 | 12985 | 0.450 |
Why?
|
Radiosurgery | 1 | 2021 | 1305 | 0.420 |
Why?
|
Angiogenesis Inhibitors | 2 | 2019 | 2037 | 0.410 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2016 | 384 | 0.400 |
Why?
|
Protein Kinase Inhibitors | 3 | 2022 | 5502 | 0.360 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2634 | 0.340 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4832 | 0.340 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1045 | 0.320 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2021 | 3571 | 0.320 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2016 | 5154 | 0.300 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 4791 | 0.290 |
Why?
|
Immunotherapy | 2 | 2019 | 4391 | 0.280 |
Why?
|
Piperazines | 1 | 2016 | 2480 | 0.260 |
Why?
|
Pyrazoles | 1 | 2015 | 1963 | 0.260 |
Why?
|
Neoplasms | 9 | 2022 | 21507 | 0.250 |
Why?
|
Androgen Antagonists | 2 | 2023 | 1343 | 0.240 |
Why?
|
Caregivers | 2 | 2012 | 2067 | 0.230 |
Why?
|
Pyridines | 1 | 2015 | 2810 | 0.230 |
Why?
|
Androgen Receptor Antagonists | 1 | 2023 | 112 | 0.220 |
Why?
|
Prostatic Neoplasms | 5 | 2022 | 10999 | 0.210 |
Why?
|
Terminal Care | 1 | 2012 | 1688 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 251 | 0.180 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 316 | 0.170 |
Why?
|
Rhabdoid Tumor | 1 | 2021 | 211 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 9122 | 0.150 |
Why?
|
Orotate Phosphoribosyltransferase | 1 | 2017 | 5 | 0.150 |
Why?
|
Orotidine-5'-Phosphate Decarboxylase | 1 | 2017 | 9 | 0.150 |
Why?
|
Autopsy | 1 | 2021 | 1004 | 0.150 |
Why?
|
Molecular Targeted Therapy | 3 | 2018 | 2727 | 0.150 |
Why?
|
Palliative Care | 1 | 2012 | 3461 | 0.150 |
Why?
|
Retreatment | 1 | 2018 | 603 | 0.140 |
Why?
|
Androgens | 1 | 2023 | 1270 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2019 | 812 | 0.130 |
Why?
|
Culture Media | 1 | 2017 | 902 | 0.130 |
Why?
|
Drug Synergism | 1 | 2019 | 1792 | 0.130 |
Why?
|
Acrylamides | 1 | 2016 | 250 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 540 | 0.120 |
Why?
|
Humans | 32 | 2023 | 739398 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1574 | 0.120 |
Why?
|
Glomerular Filtration Rate | 1 | 2021 | 2184 | 0.120 |
Why?
|
Multienzyme Complexes | 1 | 2017 | 687 | 0.110 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2016 | 618 | 0.110 |
Why?
|
Neoplastic Stem Cells | 1 | 2021 | 1380 | 0.110 |
Why?
|
Biopsy, Needle | 1 | 2018 | 1637 | 0.110 |
Why?
|
Mutation | 5 | 2023 | 29658 | 0.110 |
Why?
|
Male | 19 | 2023 | 349022 | 0.110 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4182 | 0.110 |
Why?
|
Aged, 80 and over | 8 | 2022 | 57650 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1414 | 0.100 |
Why?
|
Tissue Distribution | 1 | 2016 | 2345 | 0.100 |
Why?
|
Uric Acid | 1 | 2017 | 753 | 0.100 |
Why?
|
Drug Interactions | 1 | 2016 | 1456 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 2688 | 0.100 |
Why?
|
Aniline Compounds | 1 | 2016 | 990 | 0.100 |
Why?
|
Marital Status | 1 | 2012 | 435 | 0.090 |
Why?
|
Venous Thromboembolism | 1 | 2022 | 1673 | 0.090 |
Why?
|
Neoplasm Staging | 3 | 2021 | 10961 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3453 | 0.090 |
Why?
|
Aged | 12 | 2022 | 162698 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2021 | 3508 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1941 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2196 | 0.080 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2639 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2022 | 8400 | 0.080 |
Why?
|
Bereavement | 1 | 2011 | 273 | 0.080 |
Why?
|
Middle Aged | 12 | 2022 | 212863 | 0.070 |
Why?
|
Sex Distribution | 1 | 2012 | 2296 | 0.070 |
Why?
|
Female | 12 | 2021 | 378853 | 0.070 |
Why?
|
Age Distribution | 1 | 2012 | 2904 | 0.070 |
Why?
|
Medical Oncology | 2 | 2022 | 2217 | 0.070 |
Why?
|
Chromosomes, Mammalian | 1 | 2006 | 150 | 0.070 |
Why?
|
Survival Analysis | 2 | 2021 | 10247 | 0.060 |
Why?
|
Educational Status | 1 | 2012 | 2514 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2012 | 2564 | 0.060 |
Why?
|
NFATC Transcription Factors | 1 | 2006 | 380 | 0.060 |
Why?
|
Treatment Outcome | 3 | 2018 | 62693 | 0.060 |
Why?
|
Attitude to Health | 1 | 2012 | 2047 | 0.060 |
Why?
|
Quinuclidines | 1 | 2022 | 25 | 0.050 |
Why?
|
Models, Biological | 1 | 2019 | 9609 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9812 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 7897 | 0.050 |
Why?
|
Tennessee | 1 | 2021 | 117 | 0.050 |
Why?
|
Receptors, Chemokine | 1 | 2004 | 669 | 0.050 |
Why?
|
Gene Dosage | 1 | 2006 | 1251 | 0.050 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5148 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2022 | 341 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 12948 | 0.050 |
Why?
|
Muscle, Skeletal | 2 | 2007 | 4920 | 0.050 |
Why?
|
Muscle Proteins | 1 | 2006 | 1158 | 0.050 |
Why?
|
Censuses | 1 | 2021 | 199 | 0.050 |
Why?
|
Grief | 2 | 2012 | 247 | 0.040 |
Why?
|
Boston | 1 | 2012 | 9314 | 0.040 |
Why?
|
Adult | 8 | 2023 | 213394 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
Signal Transduction | 2 | 2021 | 23355 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 551 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 28901 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3854 | 0.040 |
Why?
|
Risk Factors | 5 | 2021 | 71974 | 0.040 |
Why?
|
Survival Rate | 1 | 2012 | 12761 | 0.040 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2021 | 449 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 831 | 0.040 |
Why?
|
Down Syndrome | 1 | 2006 | 873 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 704 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 727 | 0.040 |
Why?
|
Gene Expression | 2 | 2007 | 7788 | 0.040 |
Why?
|
Wound Healing | 1 | 2007 | 2768 | 0.030 |
Why?
|
Regeneration | 1 | 2004 | 1467 | 0.030 |
Why?
|
Point Mutation | 1 | 2021 | 1626 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2901 | 0.030 |
Why?
|
Prevalence | 1 | 2012 | 15153 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2021 | 984 | 0.030 |
Why?
|
Administration, Oral | 1 | 2022 | 3909 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2023 | 2102 | 0.030 |
Why?
|
Warfarin | 1 | 2022 | 1484 | 0.030 |
Why?
|
Reference Values | 1 | 2021 | 4983 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 2913 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2023 | 11347 | 0.030 |
Why?
|
Young Adult | 2 | 2018 | 56255 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20055 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 13635 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2021 | 1936 | 0.030 |
Why?
|
Fluorouracil | 1 | 2017 | 1609 | 0.030 |
Why?
|
Mental Disorders | 1 | 2012 | 6570 | 0.030 |
Why?
|
Hemorrhage | 1 | 2022 | 3441 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2845 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 23294 | 0.020 |
Why?
|
Family Therapy | 1 | 2011 | 207 | 0.020 |
Why?
|
Inpatients | 1 | 2021 | 2478 | 0.020 |
Why?
|
Cell Culture Techniques | 1 | 2017 | 1662 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9387 | 0.020 |
Why?
|
Mice | 5 | 2021 | 81002 | 0.020 |
Why?
|
Cohort Studies | 2 | 2021 | 40389 | 0.020 |
Why?
|
Retrospective Studies | 3 | 2021 | 76631 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4424 | 0.020 |
Why?
|
Hospices | 1 | 2011 | 264 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7144 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3672 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 5462 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2006 | 12049 | 0.020 |
Why?
|
Anticoagulants | 1 | 2022 | 4582 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6516 | 0.020 |
Why?
|
Genomics | 1 | 2022 | 5652 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 2021 | 7709 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14740 | 0.020 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2006 | 230 | 0.020 |
Why?
|
Computer Systems | 1 | 2007 | 484 | 0.020 |
Why?
|
Myogenin | 1 | 2004 | 58 | 0.020 |
Why?
|
Pyrimidines | 1 | 2017 | 2918 | 0.020 |
Why?
|
Glucose | 1 | 2017 | 4377 | 0.020 |
Why?
|
Wounds, Penetrating | 1 | 2007 | 306 | 0.020 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 126 | 0.020 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5272 | 0.020 |
Why?
|
MyoD Protein | 1 | 2004 | 152 | 0.020 |
Why?
|
Freezing | 1 | 2004 | 308 | 0.020 |
Why?
|
Macrophage-1 Antigen | 1 | 2004 | 290 | 0.010 |
Why?
|
Receptors, CCR2 | 1 | 2004 | 213 | 0.010 |
Why?
|
Animals | 5 | 2021 | 168368 | 0.010 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2007 | 555 | 0.010 |
Why?
|
Time Factors | 2 | 2021 | 40050 | 0.010 |
Why?
|
Muscle Strength | 1 | 2007 | 582 | 0.010 |
Why?
|
Transgenes | 1 | 2006 | 1010 | 0.010 |
Why?
|
Coloring Agents | 1 | 2004 | 564 | 0.010 |
Why?
|
Muscle Contraction | 1 | 2007 | 1240 | 0.010 |
Why?
|
Myositis | 1 | 2004 | 248 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10208 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2017 | 3485 | 0.010 |
Why?
|
Calcium-Binding Proteins | 1 | 2006 | 1078 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8274 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 16646 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2004 | 2503 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 1352 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 4743 | 0.010 |
Why?
|
Extracellular Matrix | 1 | 2007 | 1734 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2007 | 3922 | 0.010 |
Why?
|
Mental Health | 1 | 2012 | 2946 | 0.010 |
Why?
|
Mice, Inbred C57BL | 2 | 2007 | 21863 | 0.010 |
Why?
|
Fibrosis | 1 | 2004 | 2024 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2012 | 4212 | 0.010 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2006 | 2455 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3493 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6174 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2007 | 2394 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15511 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2006 | 9734 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2004 | 3280 | 0.010 |
Why?
|
United States | 1 | 2020 | 69573 | 0.010 |
Why?
|
Depression | 1 | 2011 | 7689 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9714 | 0.010 |
Why?
|
Macrophages | 1 | 2004 | 5631 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2004 | 14558 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2004 | 13002 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16301 | 0.010 |
Why?
|
Inflammation | 1 | 2007 | 10534 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2006 | 18003 | 0.000 |
Why?
|